Last updated: May 31, 2026
CellCept’s active ingredient and finished-dose supply chain is concentrated among large, vertically integrated pharma manufacturers and specialized generics/contract manufacturers. The practical supplier set for procurement is the labeler on the FDA label (finished drug) plus contracted API and sterile/solid-dose manufacturing used by that labeler.
Which companies supply CellCept (mycophenolate mofetil) finished drug in the US?
Short answer: CellCept’s US market supply is driven by the FDA labeler(s) for the branded product and by authorized generics listed as “AB-rated” or substitutes under the same FDA application strategy. The key procurement identifiers are the FDA label (labeler/manufacturer fields) for each NDC strength and dosage form, and the Controlled Correspondence / manufacturing sites disclosed for that application.
What to check on labels and NDCs when sourcing CellCept
Procurement teams typically map supply by:
- NDC (strength and dosage form): 250 mg capsules, 500 mg tablets, and common pack configurations.
- Labeler and manufacturer lines on the carton and package insert.
- FDA’s SPL/NDC Directory entries for each NDC.
- cGMP site: plant addresses and change history tied to the application.
Which dosage forms change supplier availability?
Supply can differ by:
- Capsules vs tablets (different manufacturing lines, different packaging, different conversion/film-coating for tablets).
- Strength (250 mg vs 500 mg often has different site usage and different fill-finish vendors for packaging).
What API suppliers make mycophenolate mofetil for CellCept?
Short answer: Mycophenolate mofetil (MMF) API sourcing is typically handled by specialized API makers and global fine-chemical manufacturers, with branded labelers using pre-qualified API suppliers and supply agreements that can shift with regulatory filings and site qualification.
How API supplier identification is done in practice
API “suppliers” for branded product are rarely marketed publicly as the final buyer-facing entity. Instead, teams infer API source from:
- DMF references in the FDA application package (when accessible via regulatory filings).
- Manufacturing site disclosures tied to the application and changes to the API manufacturing process.
- Import records (customs data) and lot-level information (where available).
How many CellCept suppliers are in the market by NDC strength?
Short answer: Counts are NDC-specific and fluctuate with authorized generic availability, manufacturing reassignments, and pharmacy distribution channel inventory.
Supplier diversity by strength (procurement view)
- A single strength can have multiple sources depending on whether the product is distributed as brand inventory vs authorized generic supply.
- The most stable approach is to qualify suppliers at the NDC level and keep an alternate qualified source for each NDC/pack combination.
What manufacturing models supply CellCept: direct manufacture or contract manufacturing?
Short answer: CellCept finished-dose supply can come from:
- Branded manufacturer sites producing directly under the NDA, and/or
- Contract manufacturing organizations (CMOs) producing dosage forms or bulk/tablet-capsule filling steps under quality agreements.
Where CMO risk shows up for sourcing
- Lead-time volatility tied to CMO batch schedules.
- Lot release delays if quality investigations or deviations occur.
- Packaging component shortages (bottles, blisters, induction seals).
What regulatory status drives supplier qualification for CellCept?
Short answer: Supplier qualification is driven by FDA compliance history, site inspections, and whether the supplier’s manufacturing process is the one covered by the relevant NDA/ANDA.
What approvals matter for procurement continuity
- NDA coverage for branded CellCept manufacturing and labeling
- ANDA coverage for authorized generics/substitutes
- Changes to manufacturing sites (post-approval CMC supplements) which can require pre-approval or reporting depending on the change
What Orange Book information matters for sourcing?
Short answer: The Orange Book indicates which applications compete for substitution and which application is the reference listed drug (RLD). For sourcing, it helps identify:
- The RLD for CellCept
- Potential generic/authorized generic substitutes
- Associated patent estates and exclusivity that can influence near-term supply allocations
How Orange Book listings translate to supplier options
If multiple ANDAs are AB-rated for the same strength/dosage form, buyers can route around brand bottlenecks by qualifying those sources and verifying:
- Bioequivalence performance
- Label claims and excipient profile alignment where relevant
- Batch availability and lot release performance
When does CellCept supplier supply tighten?
Short answer: Supply tightening typically aligns with one or more of these events:
- CMO/site disruptions (inspection findings, capacity limits, process validation delays)
- Global API shortages or upstream raw material constraints
- Packaging component shortages
- Seasonal demand spikes after transplant center scheduling shifts
Operational indicators buyers track
- FDA manufacturing site inspection outcomes (including warning letters or import alerts when they occur)
- Visible distribution outages at specific NDCs
- Increases in backorders tied to a subset of labeler/NDC combinations
What generic entry risks affect CellCept sourcing and supplier continuity?
Short answer: As generic and authorized generic capacity fluctuates, buyers see:
- Periodic availability changes across NDCs
- Temporary reliance on fewer labelers
- Pricing shifts driven by manufacturing allocations and lot release bottlenecks
Paragraph IV and litigation can indirectly affect supply
Even when litigation does not pause manufacturing, settlement terms can delay or limit certain generic launches, concentrating supply through remaining sources.
Key Takeaways
- CellCept procurement is best managed at the NDC strength and dosage form level, using the FDA labeler/manufacturer and verified manufacturing sites.
- API supplier identification is typically indirect and relies on regulatory filings (DMF references and CMC disclosures) plus quality-agreement transparency.
- Supply continuity risk comes from CMO/site capacity, packaging component availability, and upstream API constraints, not from the therapeutic use profile of mycophenolate mofetil.
- Orange Book mapping helps identify substitutable sources that can de-risk brand supply disruptions when multiple ANDAs are AB-rated.
FAQs
1) How do I identify the real manufacturer behind a CellCept NDC?
Check the NDC Directory and the FDA labeler/manufacturer fields on the carton and insert for the exact strength and dosage form.
2) Are CellCept tablets and capsules supplied by the same manufacturing sites?
Not necessarily. Site and line usage can differ by dosage form, so qualify suppliers separately for tablets vs capsules.
3) Can I source CellCept through authorized generics to avoid brand shortages?
Yes, if an AB-rated substitute exists for the same strength/dosage form, and the supplier is qualified through quality agreements and lot release history.
4) What are the biggest upstream risks for mycophenolate mofetil supply?
MMF API availability and fine-chemical input constraints, plus potential shifts in API manufacturing site qualification.
5) What documents should a sourcing team require from CellCept suppliers?
COA, CoC, GMP/cGMP compliance evidence, batch manufacturing records summaries where permitted, and quality agreement terms that cover change control and deviation notification.
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- FDA. (n.d.). NDC Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/ndc-directory
- FDA. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
